Investigational Drugs

Investigational drugs for NAFLD are derived from global clinical trials with the latest progress, and detailed drug properties are extracted from DrugBank and PubChem. For each drug, related therapeutic strategies, targets, and clinical trials in NAFLDkb are presented with knowledge graphs.

stats1
stats2

Search for:

     Peroxisome proliferator-activated receptor gamma
12 records.
Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D033 Bezafibrate Chemical drug DB01393 PPARA agonist; PPARD agonist; PPARG agonist; NR1I2 partial agonist Improve insulin resistance; Anti-inflammatory Under clinical trials Details
D092 Curcumin Chemical drug DB11672 PPARG; COX inhibitor Anticancer agent; NSAID Under clinical trials Details
D105 DHA Chemical drug DB03756 PPARA ligand; PPARG ligand Anti-inflammatory Under clinical trials Details
D119 Elafibranor Chemical drug DB05187 PPARA; PPARD; PPARG Anti-inflammatory Failed in clinical trials Details
D125 Epanova Chemical drug DB11133 PPARG ligand; PPARA activator Enhance lipid metabolism Under clinical trials Details
D208 Lobeglitazone Chemical drug DB09198 PPARG activator Improve insulin resistance Under clinical trials Details
D258 Omega 3 PUFA Chemical drug DB11133 PPARG ligand; PPARA activator Hypolipidemic drug Under clinical trials Details
D275 Pioglitazone Chemical drug DB01132 PPARG agonist Improve insulin resistance Advanced in clinical trials Details
D311 Rosiglitazone Chemical drug DB00412 PPARG agonist; PPARA; PPARD Improve insulin resistance Failed in clinical trials Details
D360 Telmisartan Chemical drug DB00966 PPARG partial agonist Improve insulin resistance Under clinical trials Details
D378 Troglitazone Chemical drug DB00197 PPARG agonist; PPARD; PPARA Improve insulin resistance Under investigation Details
D527 EPA/DHA Supplement DB11133 -- -- Under clinical trials Details